In the US, Lubiprostone (lubiprostone systemic) is a member of the drug class chloride channel activators and is used to treat Constipation, Constipation - Chronic, Constipation - Drug Induced, Irritable Bowel Syndrome and Opioid-Induced Constipation.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid (WHO)
Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11α)- (USAN)
- Lubiprostonum (Latin)
- Lubiproston (German)
- Lubiprostone (French)
- Lubiprostona (Spanish)
- Lubiprostone (OS: USAN, JAN, BAN)
- RU-0211 (IS: RTechUeno)
- SPI-0211 (IS: Sucampo)
Sucampo, United States; Sucampo Pharma, Japan; Sucampo Pharma, Netherlands; Sucampo Pharma Europe, United Kingdom; Takeda Pharma, Switzerland
|BAN||British Approved Name|
|IUPAC||International Union of Pure and Applied Chemistry|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.